Navigation Links
Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
Date:2/7/2011

nts included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the potential regulatory approval and commercialization of fidaxomicin, future activities conducted under the collaboration and license agreement, the potential benefits of the collaboration and license agreement, Optimer's potential receipt of up-front, milestone and royalty payments, the incidence of CDI and limitations of current treatment options. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's and Astellas' respective businesses including, without limitation, risks relating to: the implementation and continuation of the collaboration and license agreement, each party's performance of its respective obligations under the collaboration and license agreement, Optimer's and Astellas' ability to commercialize fidaxomicin, the ability to maintain market exclusivity for fidaxomicin in the territory, Astellas' ability to terminate the collaboration and license agreement, the development of alternative treatments for or means of preventing CDI, whether and when regulatory authorities will review or approve Optimer's or Astellas' applications for marketing approval of fidaxomicin, whether healthcare professionals will prescribe fidaxomicin, if approved, whether fidaxomicin will receive reimbursement coverage from healthcare payors and government agencies, the timing and receipt of payments and fees, if any, from Astellas and other risks detailed in Optimer's filings with the Securities and Exchange Commission. ContactsOptimer Ph
'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Today the U.S. Food and Drug Administration ... prevention of serogroup B meningococcal disease in ... Trumenba®, which received FDA approval in October, represent a ... "I have heard over and over ...
(Date:1/23/2015)... Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) released ... care leaders and a new study analyzing the impact of increased ... a nationwide coalition working to educate policy makers and the public ... Capitol was focused on how the Iowa ...
(Date:1/23/2015)... 2015 More than a third of reproductive-aged women enrolled ... private insurance, filled a prescription for an opioid pain medication ... week,s Morbidity and Mortality Weekly Report (MMWR). ... moderate to severe pain.  They are also found in some ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... 29, 2012 Nano Mask Inc., (NMI) (NANM.PK), a ... wellness related markets, today announced that it has ... Tamayz Medical, Inc. (the distributor), a Middle Eastern ... . Tamayz has agreed to purchase a minimum ...
... N.J., March 29, 2012  Aided by the launch of Rx-to-OTC ... allergy relief products grew 16.3% in 2011 to become the ... to the Nonprescription Drugs USA 2011 report by ... The U.S. OTC drug market posted a gain of 2.4% ...
Cached Medicine Technology:Nano Mask Enters Into Five Year $13,000,000 Middle East Distribution Agreement with Tamayz Medical 2Strong Rx-to-OTC Switch Performance and Holistic Marketing Drive Solid OTC Drug Market Growth in 2011, According to Kline 2Strong Rx-to-OTC Switch Performance and Holistic Marketing Drive Solid OTC Drug Market Growth in 2011, According to Kline 3
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
(Date:1/22/2015)... 2015 JJsHouse.com is a famous dress online ... business announces its latest collection of wedding dresses , ... important issue is the wedding dress on your big day; ... woman’s life. Every bride wants to find the most suitable ...
(Date:1/22/2015)... 2015 State Forestry Institute of Mecklenburg-Vorpommern ... with support from GEOSYSTEMS, a dedicated Hexagon Geospatial and ... leverage Hexagon Geospatial’s ERDAS APOLLO for cataloging, ... as point clouds and documents. This effort will enable ...
Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... INETICO, Inc. and TPABenefits, Inc.,of San Antonio, ... interface,between the INETICO system and the TPABenefits Web ... Claims Management, Pre-Certification,and Wellness data source and allows ... Pre-Certifications and Case Notes on the,TPABenefits Web Portal., ...
... The region,s leading health,insurer, Independence Blue Cross ... Jefferson Health System (JHS), announced today that they ... new agreements are effective June 1, 2008, and ... services at the following,Jefferson Health System acute-care hospitals: ...
... 8 Collaboration among a,broad set of ... of the largest,issues facing the health care ... a report released today by the American,Association ... http://www.newscom.com/cgi-bin/prnh/20060126/CLTH062LOGO ), The annual ...
... any account, the platypus is an odd creature. Its got ... swims more like a beaver.yet it lays eggs and can inject ... an elaborate hoax by scientists who examined the first specimen pelt ... 1799. , In the May 9 issue of Nature, a consortium ...
... is a leading risk factor for osteoarthritis (OA), a ... can aggravate the toll on almost any joint, obesity ... OA and an increase in total hip arthroplasty (THA). ... to postsurgical complications, however, remains open to debate and ...
... babies born each year in Washington to smoking mothers, ... best things a woman can do to protect her own ... Day on May 11, the state,Department of Health has added ... women with more help when they,re ready to quit using,tobacco., ...
Cached Medicine News:Health News:INETICO, Inc. Creates Data Interface with TPABenefits, Inc. Offering a Powerful Care and Claims Management Solution 2Health News:Independence Blue Cross, Jefferson Health System Reach Agreement on New Three-Year Contracts 2Health News:PPO Industry Calls for Increased Collaboration Among Non-Traditional Allies 2Health News:PPO Industry Calls for Increased Collaboration Among Non-Traditional Allies 3Health News:CSHL scientists are part of consortium that sequences platypus genome 2Health News:CSHL scientists are part of consortium that sequences platypus genome 3Health News:Obese patients face increased risks for infection and dislocation following revision hip surgery 2Health News:Obese patients face increased risks for infection and dislocation following revision hip surgery 3Health News:Tobacco Quit Line Expands Services for Pregnant Women Who Smoke 2
... The Hgb Pro Professional Hemoglobin Testing ... and single-use test strips, used in measuring ... blood. The Hgb Pro provides the precision, ... require., ,The Hgb Pro Professional Hemoglobin Testing ...
... is a fully automated analyzer that requires ... time by the operator. The Variant II ... tubes. It reads the bar code, samples ... the specimen into the chromatographic station for ...
... The Advia 70 hematology system ... 5-part differential. Designed for speed ... analyzer combines cost-effectiveness with impressive ... suitable either on its own ...
AcT 5diff OV enables low-volume labs to advance to 5-part differential analysis at an affordable price. This analyzer delivers accurate test results and a user-friendly software interface in a compac...
Medicine Products: